Kaleido BioSciences
Kaleido BioSciences is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Kaleido BioSciences.
Kaleido BioSciences is a company.
Key people at Kaleido BioSciences.
Key people at Kaleido BioSciences.
Kaleido Biosciences is a clinical-stage biotechnology company developing Microbiome Metabolic Therapies (MMTs), novel small-molecule chemistries that modulate the metabolic output of the human microbiome to treat diseases like immune-driven conditions, metabolic disorders, and infections.[1][2][3] It serves patients with unmet needs in areas such as urea cycle disorders, hepatic encephalopathy, ulcerative colitis, and immuno-oncology, addressing limitations of traditional microbiome approaches like fecal transplants or antibiotics by targeting microbial metabolism directly.[1][3] The company, founded in 2015 and headquartered in Bedford, Massachusetts, advanced multiple Phase 1/2 trials by 2020-2021 but faced program discontinuations, with a low market cap signaling challenges in sustaining growth momentum.[3][4][6]
Kaleido Biosciences emerged from Flagship Pioneering in 2015, founded by Geoffrey von Maltzahn and Noubar Afeyan as part of Flagship's decade-long investment in microbiome science.[2][3][5] Operating in stealth mode initially, it was publicly unveiled in September 2017 with $65 million in funding and Mike Bonney—former CEO of Cubist Pharmaceuticals—appointed as CEO and board chair.[2] The idea stemmed from Flagship's expertise in companies like Seres Therapeutics and Evelo Biosciences, focusing on a chemistry-driven platform rather than live bacteria to shift microbiome metabolism for health benefits.[2] Early traction included generating over 3,000 days of human data across 20+ studies, rapidly advancing candidates via ex vivo screening, animal models, and food-regulated human trials.[2][3]
Kaleido rides the microbiome therapeutics wave, capitalizing on growing evidence linking gut microbiome imbalances to diseases like autoimmune conditions, metabolic syndrome, and infections—a largely untapped frontier in healthcare.[1][3] Timing aligns with post-2015 advances in microbiome science, accelerated by Flagship's ecosystem and the COVID-19 era's focus on immune modulation (e.g., KB-109 for mild COVID).[3][6] Market forces favoring it include rising demand for non-antibiotic solutions amid resistance crises and precision therapies for chronic diseases, influencing the ecosystem by pioneering metabolic modulation over microbial transplantation.[1][2] Its Flagship roots amplify impact, contributing to a network of microbiome innovators reshaping biotech from gut health to systemic therapies.[2]
Several pipeline candidates like KB-174, KB-109, and Onterodrimer have been discontinued, with others pending or stalled, contributing to a diminished market presence (e.g., ~$4M cap, low trading volume).[4][6] Next steps likely involve pipeline reprioritization toward high-potential areas like inflammatory bowel disease or immuno-oncology, amid trends in AI-driven microbiome mapping and combination therapies. Kaleido's influence may evolve through partnerships (e.g., COPD Foundation) or acquisition by larger players, but sustaining momentum requires clinical wins in a competitive biotech field—potentially reviving its mission to metabolically reprogram the microbiome for unmet needs.[3][6][7] This positions it as a high-risk innovator in a field where chemistry-driven precision could yet disrupt traditional paradigms.
